We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
For investors seeking momentum, First Trust Health Care AlphaDEX Fund (FXH - Free Report) is probably on radar now. The fund just hit a 52-week high, and is up about 23% from its 52-week low price of $63.96/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
FXH in Focus
This fund targets the healthcare segment of the broad U.S. market and uses the AlphaDEX methodology to select stocks from the Russell 1000 index. The approach results in a basket of 77 securities, which are widely spread across components, with none holding more than 2.65% of assets. The product has key holdings in health care providers & services, health care equipment & supplies and biotechnology. It charges investors 62 basis points a year in fees (see: all the Healthcare ETFs here).
Why the Move?
The healthcare space has been an area to watch lately given that it is among the best performing sectors this year driven by its non-cyclical nature, which provides a defensive tilt to the portfolio in a turbulent market. Additionally, rising M&A, faster drug approval and positive regulatory backdrop added to the strength.
More Gains Ahead?
Currently, FXH has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook, suggesting that the outperformance could continue in the months ahead. Further, many of the segments that make up this ETF have a strong Zacks Industry Rank, so there is definitely still some promise for those who want to ride on this surging ETF a little longer.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Healthcare ETF (FXH) Hits New 52-Week High
For investors seeking momentum, First Trust Health Care AlphaDEX Fund (FXH - Free Report) is probably on radar now. The fund just hit a 52-week high, and is up about 23% from its 52-week low price of $63.96/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
FXH in Focus
This fund targets the healthcare segment of the broad U.S. market and uses the AlphaDEX methodology to select stocks from the Russell 1000 index. The approach results in a basket of 77 securities, which are widely spread across components, with none holding more than 2.65% of assets. The product has key holdings in health care providers & services, health care equipment & supplies and biotechnology. It charges investors 62 basis points a year in fees (see: all the Healthcare ETFs here).
Why the Move?
The healthcare space has been an area to watch lately given that it is among the best performing sectors this year driven by its non-cyclical nature, which provides a defensive tilt to the portfolio in a turbulent market. Additionally, rising M&A, faster drug approval and positive regulatory backdrop added to the strength.
More Gains Ahead?
Currently, FXH has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook, suggesting that the outperformance could continue in the months ahead. Further, many of the segments that make up this ETF have a strong Zacks Industry Rank, so there is definitely still some promise for those who want to ride on this surging ETF a little longer.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>